Bluebird Bio
在场
高管
查看带有其 28 名主要高管的组织结构图
Bluebird Bio 搜索最多的简介
高管在Bluebird Bio变化
- James SterlingJames Sterling 将于20246月10作为 Chief Financial Officer 加入公司 (新闻发布的2024五月30号).
- Chris Krawtschuk, Chief Financial Officer, 将于 20246月10 退休 (新闻发布的2024五月30号).
创建提醒
跟踪 Bluebird Bio 的高管变动
生物技术
Bluebird Bio 拥有 2,334 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Cala Health 刚刚宣布为 50 筹款数百万美元。 (公布2024十二月16号).
- Angitia Biopharmaceuticals 刚刚宣布为 120 筹款数百万美元。 (公布2024十二月16号).
- Kineta and TuHura Biosciences have merged (公布2024十二月13号)..
生物技术 行业的其他推荐联系人
消息
Bluebird Bio 的最新新闻稿
- press releases | bluebird bio, Inc.
- FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions | bluebird bio, Inc.
- FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy | bluebird bio, Inc.
- bluebird bio stock trading halted today June 9th and tomorrow June 10th | bluebird bio, Inc.
- bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting | bluebird bio, Inc.
- bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress | bluebird bio, Inc.
- bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) - bluebird bio, Inc.
- bluebird bio to Present at Jefferies Cell Therapy Virtual Summit - bluebird bio, Inc.
- bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency - bluebird bio, Inc.
- U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) - bluebird bio, Inc.
- View more press releases Close
通过电子邮件
